Clinical Trials
32 trialsCombinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer
Regeneron Pharmaceuticals
Real-World Outcomes of First-Line Nivolumab + Ipilimumab With Chemotherapy in Non-Small Cell Lung Cancer in Poland
Bristol-Myers Squibb
PRIMM
University Medical Centre Maribor
Evaluate the Efficacy and Safety of Serplulimab Plus Chemotherapy in Neoadjuvant and Adjuvant Treatment of Resectable NSCLC (ECTOP-1013)
Fudan University
CLASSIC5
Hunan Province Tumor Hospital
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
Celldex Therapeutics
Preoperative Chemoradiotherapy vs. Chemotherapy Alone in NSCLC Patients
Swiss Cancer Institute
Efficacy of Targeted Therapy Combined Chemotherapy in Advanced EGFR Positive NSCLC Patients
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
CHIVA
Intergroupe Francophone de Cancerologie Thoracique
A Study Evaluating the Efficacy and the Safety of First-line Chemotherapy Combined With the Therapeutic Vaccine Named TG4010 and Nivolumab in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC)
Transgene
Combination Chemotherapy, Radiation Therapy, and RSR13 in Treating Patients With Stage III Non-small Cell Lung Cancer
Spectrum Pharmaceuticals, Inc
Chemoradiotherapy in Stage III Non-small Cell Lung Cancer (NSCLC)
Intergroupe Francophone de Cancerologie Thoracique
Biological Factors Predicting Response to Chemotherapy in Advanced Non Small Cell Lung Cancer
European Lung Cancer Working Party
Genotype-Driven Treatment of Advanced Non-small Cell Lung Cancer Based on mRNA Expression of ERCC1 & RRM1 as First-line Chemotherapy
Yonsei University
Fludeoxyglucose F 18 in Detecting Lymph Node Metastasis in Patients With Stage I or Stage II Non-Small Cell Lung Cancer That Can Be Removed by Surgery
Roswell Park Cancer Institute
Erlotinib Treatment Beyond Progression in EGFR Mutant NSCLC
Finnish Lung Cancer Group
CERTO
Merck KGaA, Darmstadt, Germany
Carboplatin, Paclitaxel, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed During Surgery
Alliance for Clinical Trials in Oncology
Hypofractionated Radiation Therapy Combined With Concurrent Chemotherapy for Patients With Non-small Cell Lung Cancer
North China Petroleum Bureau General Hospital
Multimodality Treatment for Patients With Resectable Non-Small Cell Lung Cancer (NSCLC) - BEACON Study: Bevacizumab and Chemotherapy for Operable NSCLC
Memorial Sloan Kettering Cancer Center
Progression Free Survival (PFS) Using Erlotinib for Non-Small-Cell Lung Cancer (NSCLC) in Chinese Population
Hoffmann-La Roche
Evaluation Of The Efficacy Of The Combination Of Axitinib With Pemetrexed And Cisplatin In The Treatment Of Non-Squamous Non-Small Cell Lung Cancer
Pfizer
A Study of Erlotinib (Tarceva) Versus Gemcitabine/Cisplatin as First-line Treatment in Patients With Non-small Cell Lung Cancer With EGFR Mutations
Hoffmann-La Roche
Fondaparinux (Arixtra) With Chemotherapy for Advanced Non-Small Cell Lung Cancer
University of Alabama at Birmingham
Once Weekly Radiation for Lung Cancer With Chemotherapy
Clinical Oncology Research Associates
Combination of Weekly Chest Radiotherapy and Oral Navelbine for the Palliation of Advanced Non Small Cell Lung Cancer: A Phase I Study
Clinical Oncology Research Associates
Optimization of Treatment of Advanced Nonsmall Cell Lung Cancer Using Radiotherapy and Chemotherapy
International Atomic Energy Agency
Paclitaxel Plus Radiation Therapy in Treating Patients With Untreated Stage III Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Concurrent and Non-concurrent Chemo-radiotherapy or Radiotherapy Alone for Patients With Oligo-metastatic Stage IV Non-small Cell Lung Cancer (NSCLC)
Maastricht Radiation Oncology
Vaccine Therapy in Treating Patients With Stage I, Stage II, or Stage IIIA Non-small Cell Lung Cancer or With Stage I or Stage II Mesothelioma
Roswell Park Cancer Institute
CPG 7909 Injection in Non-Small Cell Lung Cancer
Pfizer
Ph I:Bevacizumab + Chemotherapy in Pts w/Malig Pleural Effusion Due to Adv NSCLC
Memorial Sloan Kettering Cancer Center